Research Antibodies Market Size, Share & Trends Analysis Report By Product (Primary, Secondary), By Type, By Technology, By Source, By Application, By End-use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030
The global Research Antibodies market size was estimated at USD 1.51 billion in 2021 and is expected to surpass around USD 2.85 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 5.13% during the forecast period 2022 to 2030.
- By Product, the U.S. Research Antibodies market was valued at USD 482.1 million in 2021 and expected to witness growth at a CAGR of 4.20% from 2022 to 2030.
- In 2021, the primary product segment held the largest revenue share due to the higher specificity and direct detection capabilities offered by the antibodies
- By type, monoclonal antibodies captured a substantial share in 2021 due to the increase in COVID-19-related research activities involving the use of such antibodies
- The western blotting technology segment held a dominant share of over 25.8% in 2021 because of the increasing investments in R&D activities by several biotechnology and pharmaceutical companies and the rapidly growing applications of antibodies in western blots created for proteomic studies
- By end-use, academic and research institutions held the largest share of over 60.9% in 2021 due to a rise in funding opportunities and growth in the number of scientific institutions involved in life sciences
- In 2021, North America accounted for the largest share of over 35.4% due to the widespread presence of life sciences research institutions and numerous biotechnology and biopharmaceutical manufacturers in the region
Factors driving the market include a rise in R&D activities undertaken by biopharmaceutical and biotechnology companies and increase in support from government authorities. Furthermore, expansion in the scope of neurobiology and stem cell research and the availability of technologically advanced antibody production methods are expected to propel market growth.
An increase in the number of collaborative initiatives undertaken by research institutes and various public and private entities for the promotion of cell-based research is fueling market growth. The trend is more prominent in established markets, such as North America, that have an established scientific infrastructure. For instance, in March 2020, the Canadian government invested around USD 4.3 million in funds towards the Centre for Commercialization of Regenerative Medicine, which is involved in carrying out scientific studies based on cell regeneration. Moreover, in April 2021, the government announced an investment of USD 45 million over 3 years in Stem Cell Network to develop information, therapies, and technologies to benefit individuals living with chronic and severe illnesses such as COVID-19 and assess its long-term impact. Such initiatives are expected to encourage further adoption of antibody activities and enhance the growth prospects for the market.
The COVID-19 outbreak has created lucrative growth opportunities for the market. Several leading pharmaceutical companies are investing significantly in R&D for creating effective testing tools and increasing scientific understanding of the disease. The need for research antibodies has greatly increased as a result of these intense R&D operations for the development of novel vaccination and therapy techniques. Additionally, a number of public and commercial entities are making significant efforts to fund the development of COVID-19 vaccines and therapeutics. For instance, in April 2020, Emergent BioSolutions, a biopharmaceutical company, received USD 14.5 million from the federal government to work on an antibody therapy study for COVID-19.
Report Scope of the Research Antibodies Market
US$ 2.85 Billion by 2030
CAGR of 5.13% from 2022 to 2030
Fastest Growing Market
2022 to 2030
Product, type, technology, source, application, end-use and Region,
Abcam Plc; Merck KGaA; Thermo Fisher Scientific, Inc.; Cell Signalling Technology, Inc.; Santa Cruz Biotechnology Inc.; PerkinElmer, Inc.; Becton; Dickinson and Company; Bio-Techne Corporation; Proteintech Group, Inc.; Jackson ImmunoResearch Inc.
The primary antibodies segment captured the largest revenue share of over 75.4% in 2021 and is also projected to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing availability of primary antibodies using rabbits, mice, goats, and other species as hosts and the wide range of utility offered by such antibodies for applications in the R&D space. Also, owing to the usage of primary antibodies for frequently performed laboratory procedures, such as staining and imaging, the segment is predicted to grow at an exponential rate.
The secondary antibodies segment is expected to grow at a constant rate as these antibodies are more convenient and cost-effective to develop. Demand for secondary research antibodies is also anticipated to increase due to the availability of ready-to-use conjugated antibodies that can improve product development activities by assisting in the identification, grouping, and purification of targeted antigens. For instance, Thermo Fisher Scientific, Inc. provides fluorescent dye-conjugated secondary antibodies that make it easier to identify proteins in a variety of applications, including immunohistochemistry, western blotting, and fluorescent cell imaging.
The monoclonal antibodies segment accounted for a dominant share of over 60.5% in 2021 due to a sharp increase in the number of cancer research projects that demand high specificity antibodies. As monoclonal antibodies can efficiently adhere to or block antigens on cancer cells, these are employed in the identification and development of new medicines for various cancer types. This factor is expected to expand the growth prospects for the segment in the near future.
Polyclonal antibodies are projected to grow over the forecast period as these antibody structures are essential for the research aspects focusing on the purification of antigens and examination of histopathological tissue. Furthermore, polyclonal antibodies provide benefits like stability, practical storage methods, strong affinity, and excellent compatibility for ELISA and western blotting technologies, thereby propelling market growth.
The western blotting segment accounted for a dominant share of over 25.6% in 2021 due to the widespread availability and adoption of the technique. In addition, due to the increased accuracy that the western blotting technique offers, it is typically chosen over alternative technologies for applications involving the detection of important protein entities. These attributes are expected to positively affect the segment growth.
Immunohistochemistry accounted for the second-largest share in 2021. The segment is anticipated to expand steadily due to its significant applications in the detection of enzymes, antigens, tumor suppressor genes, and tumor cell growth for cell-based research. Additionally, rising R&D spending and a high level of scientific awareness regarding the technique have led to increasing growth prospects for immunohistochemistry. Furthermore, benefits provided by the technique such as high sensitivity and simplicity of use are some of the factors anticipated to drive the market.
In 2021, the rabbit segment held the largest share of over 45.7%. Rabbits are extensively used for antibody production owing to several advantages such as higher affinity antibodies provided by rabbits as compared to those obtained from other animal hosts. Furthermore, the higher specificity provided by these antibodies makes them ideal for the detection of small molecules, hormones, toxins, and other biologically important substances.
The mouse segment is anticipated to witness considerable growth over the forecast period. Mice have been predominantly used in the production of antibodies due to their high reproduction rate and smaller size. Furthermore, the main factor influencing their widespread use is the structural similarity between mouse and human antibodies, which can significantly drive their adoption for R&D applications.
The oncology segment accounted for the largest share of over 30.8% in 2021 owing to a rise in the prevalence of cancer in key geographies. According to the American Cancer Society, in 2021, over 1.9 million new cancer cases were recorded in the U.S. Additionally, over 608,570 cancer deaths were also recorded in the same year in the U.S. As a result, more research antibodies will likely be used for designing and evaluating of new diagnostic and therapeutic approaches for the mitigation of cancer.
The stem cells segment is expected to witness significant growth owing to an increase in the number of stem cell research activities globally. The growth is also attributed to an increase in the adoption of stem cells for the treatment of a wide range of chronic ailments such as diabetes, cancer, Alzheimer’s, Parkinson’s, rheumatoid arthritis, and kidney and lung diseases. Furthermore, antibodies are used for stem cell research areas that include disease modeling, developmental biology, drug screening, reprogramming techniques development, and cell therapy that can positively affect market growth.
The academic and research institutions segment captured the largest revenue share of over 60.9% in 2021 and is projected to grow at the fastest rate throughout the forecast period. This can be attributed to the increase in scientific initiatives by such centers for the development of novel therapies and tests for chronic diseases. For instance, in January 2021, researchers at The University of Texas Medical Branch at Galveston (UTMB Health) and The University of Texas Health Science Center at Houston (UTHealth) discovered two novel antibodies CoV2-06 and CoV2-14 for a potential novel antibody therapy for COVID-19 infection. Such initiatives can positively affect segment growth in the near future.
Pharmaceutical and biotechnology companies are expected to grow at a significant rate over the forecast period due to the increase in R&D activities in the life sciences domain. Furthermore, the increasing importance of antibodies for the development of novel biologic products and rising demand for quality control applications for various techniques, such as PCR and electrophoresis, are likely to boost segment growth.
North America dominated the market in 2021 with a revenue share of over 35.4%. Growing focus on biomedical, stem cells and cancer research is a major contributor to the industry's growth. The regional growth is also favored by the presence of key players such as Thermo Fisher Scientific, Inc. and PerkinElmer, Inc. There is also an increasing number of biotechnology and biopharmaceutical firms in the region that are focusing on life sciences innovations, which is expected to fuel the industry expansion.
The market in Asia Pacific is expected to grow at the fastest rate over the forecast period as a result of an increase in collaborative activities carried out by academic institutions. For instance, in June 2019, scientists from Tsinghua University, China Medical University, and the Vaccine Research Center at the NIH started a research study on the identification and characterization of HIV-1 strains and their robust and widespread resistance to a variety of neutralizing antibodies. The National Natural Science Foundation Award, China's Ministry of Science and Technology, and Gates Foundation Grand Challenges China all supported this project. As a result, such government-funded scientific activities in the region are anticipated to drive the market.
Some of the prominent players in the Research Antibodies Market include:
- Abcam Plc.
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- Cell Signalling Technology, Inc.
- Santa Cruz Biotechnology Inc.
- PerkinElmer, Inc.
- Becton, Dickinson and Company
- Bio-Techne Corporation
- Proteintech Group, Inc.
- Jackson ImmunoResearch Inc.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Research Antibodies market
- Monoclonal Antibodies
- Polyclonal Antibodies
- Western Blotting
- Flow Cytometry
- Other Technologies
- Other Sources
- Infectious Diseases
- Stem Cells
- Other Applications
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- United Kingdom
- Rest of Europe
- Southeast Asia
- Rest of Asia Pacific
- Rest of Latin America
Middle East & Africa (MEA)
- North Africa
- South Africa
- Rest of Middle East & Africa
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Research Antibodies industry analysis from 2022 to 2030 to identify the prevailing Research Antibodies industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Research Antibodies industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Research Antibodies industry trends, key players, market segments, application areas, and market growth strategies.